Based on MDA-7/IL-24's broad spectrum selective activity toward cancer cells and its multiplicity of anti-cancer effects, including “bystander” antitumor activity, anti-angiogenesis activity, direct cancer-selective apoptosis- and toxic autophagy-induction, immune modulatory activity and synergy with other therapeutic modalities, MDA-7/IL-24 holds significant promise for developing efficacious approaches for the therapy of both primary and metastatic breast cancers, as well as other types of cancer [10, 59]. Here, IL24 is linked to breast carcinoma.